Fleury SA
BOVESPA:FLRY3
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
13.6
18.58
|
Price Target |
|
We'll email you a reminder when the closing price reaches BRL.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one FLRY3 stock under the Base Case scenario is 19.4 BRL. Compared to the current market price of 13.89 BRL, Fleury SA is Undervalued by 28%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Fleury SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for FLRY3 cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Fleury SA
Balance Sheet Decomposition
Fleury SA
Current Assets | 4.2B |
Cash & Short-Term Investments | 2B |
Receivables | 1.9B |
Other Current Assets | 219.4m |
Non-Current Assets | 8.6B |
Long-Term Investments | 216.3m |
PP&E | 2.5B |
Intangibles | 5.8B |
Other Non-Current Assets | 112.8m |
Current Liabilities | 1.8B |
Accounts Payable | 676.5m |
Accrued Liabilities | 428.8m |
Other Current Liabilities | 669.4m |
Non-Current Liabilities | 5.7B |
Long-Term Debt | 4.6B |
Other Non-Current Liabilities | 1.1B |
Earnings Waterfall
Fleury SA
Revenue
|
7.5B
BRL
|
Cost of Revenue
|
-5.4B
BRL
|
Gross Profit
|
2.1B
BRL
|
Operating Expenses
|
-899.7m
BRL
|
Operating Income
|
1.2B
BRL
|
Other Expenses
|
-564m
BRL
|
Net Income
|
597m
BRL
|
Free Cash Flow Analysis
Fleury SA
BRL | |
Free Cash Flow | BRL |
FLRY3 Profitability Score
Profitability Due Diligence
Fleury SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Fleury SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
FLRY3 Solvency Score
Solvency Due Diligence
Fleury SA's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Fleury SA's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FLRY3 Price Targets Summary
Fleury SA
According to Wall Street analysts, the average 1-year price target for FLRY3 is 19.7 BRL with a low forecast of 16.16 BRL and a high forecast of 25.2 BRL.
Dividends
Current shareholder yield for FLRY3 is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Fleury SA engaged in the provision of medical diagnostic services. The company is headquartered in Sao Paulo, Sao Paulo and currently employs 20,800 full-time employees. The company went IPO on 2009-12-16. The Company’s activities are divided into three business lines: Patient Service Centers (PSC), B2B and Dental Diagnosis. The PCS division offers private medical diagnostics. The B2B division is responsible for clinical analysis and diagnostic imaging in partner hospitals, as well as tests for laboratories, hospitals and clinics throughout Brazil. The Dental Diagnosis division provides dental diagnostic imaging through Papaiz Associados Diagnosticos por Imagem SA, a joint venture with Odontoprev SA. The firm operates through several brands, such as Fleury Medicina e Saude, Clinica Felippe Mattoso e Weinmann, a+ Medicina Diagnostica, Diagnoson a+, Diagmax and Inlab, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one FLRY3 stock under the Base Case scenario is 19.4 BRL.
Compared to the current market price of 13.89 BRL, Fleury SA is Undervalued by 28%.